View More Recent Stories

Jan 29, 2025 09:12AM Cantor Fitzgerald provides update on Biotechnology stocks
Jan 27, 2025 07:14AM H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
Jan 17, 2025 06:38AM H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
Jan 13, 2025 11:23AM Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $61 at Oppenheimer
Jan 13, 2025 08:17AM Harmony Biosciences (HRMY) Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
Dec 11, 2024 07:35AM Piper Sandler Provides 'Expert Perspectives On Orexin Agonists And An Evolving Sleep/Wake Space'
Oct 30, 2024 06:10AM Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
Oct 29, 2024 05:15PM Harmony Biosciences (HRMY) Commences 8M Share Offering by Selling Stockholders
Oct 29, 2024 07:31AM Harmony Biosciences (HRMY) Tops Q3 EPS by 12c, provides guidance
Oct 18, 2024 06:12AM Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
Oct 15, 2024 05:51AM Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
Oct 10, 2024 08:21AM Raymond James Resumes Harmony Biosciences Holdings Inc. (HRMY) at Outperform
Oct 10, 2024 06:41AM Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $52 at Mizuho
Oct 2, 2024 07:29AM Piper Sandler Reiterates Overweight Rating on Harmony Biosciences (HRMY)
Oct 2, 2024 05:37AM Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
Oct 1, 2024 08:47AM Harmony Biosciences (HRMY) Highlights New Data, Robust Late-stage Pipeline With Near-term Value Creation Opportunities And Its Bold New Vision At Investor Day
Oct 1, 2024 07:12AM Mizuho Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY)
Sep 12, 2024 07:36AM Needham Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
Sep 10, 2024 05:05AM UBS Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy
Aug 8, 2024 07:08AM Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $42 at Mizuho
Aug 6, 2024 07:37AM Harmony Biosciences (HRMY) Tops Q2 EPS by $1.05, provides guidance
Jul 15, 2024 08:42AM Piper Sandler Reiterates Overweight Rating on Harmony Biosciences Holdings Inc. (HRMY)
Jun 25, 2024 11:33AM Citi on Harmony (HRMY): 'FDA Denies Short Seller Citizens’ Petition to Remove Wakix from the Market, Ending Unwarranted Safety Claims'
Jun 25, 2024 08:09AM Harmony Biosciences (HRMY) Acknowledges FDA Action Denying The Citizen Petition For Wakix
Jun 24, 2024 01:41PM Citi Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)
Jun 24, 2024 11:43AM Oppenheimer on Harmony Biosciences Holdings Inc. (HRMY): 'WAKIX Approved for EDS in Pediatric Narcolepsy, Small But Meaningful Commercial Opportunity'
Jun 24, 2024 07:03AM Harmony Biosciences (HRMY) Receives U.S. Food And Drug Administration Approval For Wakix In Pediatric Patients With Narcolepsy
Jun 20, 2024 04:29PM Citi Starts Harmony Biosciences Holdings Inc. (HRMY) at Buy
View More Recent Stories